Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.
|Deserunt mollit sunt Lorem laborum do id aliqua dolore||29 Oct 2021||Lorem|
|Biosimilar interchangeability studies to have limited benefit on US uptake without shifts in legal framework and patient, physician and payer education, experts say||30 May 2018||Shuan Sim|
|Rituximab biosimilars in Europe likely to see widespread RA uptake; originator preferred in some NHL settings – experts||22 Apr 2016||Alaric DeArment, Alissa Fleck|
|Samsung RA biosimilar EU uptake tied to perceived cost despite physician concerns – experts||11 Dec 2015||Alissa Fleck, Jennifer C. Smith-Parker|
Delivers exclusive investigative journalist content including breaking news and analysis ahead of market-moving events.
- Forward-looking, nuanced, qualitative asset analysis on development, approval & market/reimbursement potential
- Material intelligence on competitors, including breaking news
- Insight on companies’ business development needs and strategies
Insight on companies’ CRO and business development needs, strategies and relationships
Remove risk and uncertainty
Gain a competitive edge
Secure actionable leads
Premium databases is part of our industry range of products
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer